Investor Presentaiton
13
Commercial execution and innovation
Diabetes care
Novo NordiskⓇ
OzempicⓇ and Rybelsus® are driving the diabetes care sales
growth in North America Operations
Diabetes care sales and growth in North America Operations
North America Operations has been on a
journey of:
DKK billion
60
6%
50
40
40
30
20
20
10
2%
3%
5%
12%
0
2017
2018
2019
2020
2021
Injectable GLP-1 Oral GLP-1
Insulin Other Diabetes care Growth at CER
CER: Constant exchange rates
Note: Blockbuster products are products reaching USD 1 billion in sales
Transforming ~70% of US sales by 2022
Status: 60%
Notably increasing the number of
patients treated
Progress: Treating ~30% more patients
since 2017
Bringing two new blockbuster products
to the market
Progress: Ozempic® is a 3x blockbuster
and RybelsusⓇ is approaching blockbuster
status just two years after launch
CMD22
CAPITAL MARKETS DAYView entire presentation